Search
Back

Dihydroergotamine Mesylate

CAS 6190-39-2
Dihydroergotamine Mesylate

General Information

Dihydroergotamine mesilate, an ergot alkaloid, is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. It can be administered orally as a tablet, injected or administered as a nasal spray.


About the API

Technology Plant Extraction
Therapeutic category Migraine
Systematic Name ergotaman-3´,6´,18-trione,9,10-dihydro-12´-hydroxy-2´-methyl-5´-(phenylmethyl)-,(5´α)-, monomethanesulfonate
Available formulations Injectables Nasal Systemic Oral Solid Oral Solid Long-Acting
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.